AV-Comparatives Publishes World's Largest Independent Enterprise Cybersecurity Solution Test
INNSBRUCK, Austria, July 21, 2025 /PRNewswire/ -- AV-Comparatives, the globally recognised authority in independent cybersecurity testing, has released its Enterprise Security Test 2025 (March to June). This is the most extensive public evaluation to date of enterprise endpoint protection platforms (EPP), endpoint detection and response (EDR), and extended detection and response (XDR) solutions. Seventeen high-performing enterprise-grade cybersecurity products were rigorously evaluated using real-world attack simulations and scientifically sound methodologies, offering a comprehensive view of modern endpoint defence capabilities.
The report includes individual product descriptions that outline key strengths and capabilities to help IT decision-makers select the most suitable solution based on their organisation's size, infrastructure, and security priorities.
What Sets This Test Apart?
Unmatched Scope: This is the largest public comparative test of enterprise EPP, EDR, and XDR solutions globally. Only mature, high-performing products were included. These had already demonstrated consistent reliability and strong protection in previous assessments.
Holistic Analysis: Each product was evaluated across four mission-critical dimensions:
To support enterprise IT leaders, the report includes an extensive feature matrix (page 57) detailing the core and advanced capabilities of each tested solution. This includes management interfaces, deployment models, threat response tools, and third-party integration support, helping organisations make informed side-by-side comparisons.
All evaluated products represent enterprise-ready solutions that meet modern protection standards. Each product received the AV-Comparatives Approved Enterprise Product Seal, recognising their proven security effectiveness, operational reliability, and readiness for large-scale deployment.
Peter Stelzhammer, co-founder of AV-Comparatives, commented:
'CISOs and IT leaders face complex, fast-evolving threats. Independent validation is not a luxury – it is essential. This test series provides evidence-based insights into how EPP, EDR, and XDR solutions perform in the field. We apply strict, scientifically grounded methodologies to help enterprises choose wisely.'
Access the full test report:
https://www.av-comparatives.org/tests/business-security-test-2025-march-june/
AV-Comparatives' enterprise test series is ISO 9001:2015 certified for the scope of Independent Tests of Cybersecurity Solutions. It is globally trusted by CISOs, analysts, and IT leaders as the benchmark for unbiased, rigorous cybersecurity evaluation.
Cybersecurity and antivirus test results are available at www.av-comparatives.org for leading vendors including:
Avast, AVG, Avira, Bitdefender, Check Point, Cisco, CrowdStrike, Elastic, Fortinet, F-Secure, ESET, G DATA, Gen Digital, Google, Intego, K7 Computing, Kaspersky, Malwarebytes, ManageEngine, McAfee, Microsoft, NetSecurity, Nord Security, Norton, Palo Alto Networks, Rapid7, SenseOn, Sophos, Total Defense, TotalAV, Trellix, Trend Micro, VIPRE, WithSecure, and many more.
Media contact: Peter Stelzhammer, [email protected] +43512287788
Photo: https://mma.prnewswire.com/media/2733799/AV_Comparatives_Cybersecurity.jpg
Logo: https://mma.prnewswire.com/media/2608678/AV_Comparatives_Logo.jpg
View original content to download multimedia: https://www.prnewswire.com/news-releases/av-comparatives-publishes-worlds-largest-independent-enterprise-cybersecurity-solution-test-302508536.html
SOURCE AV-Comparatives
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash
Eddie Howe confirms no contract talks with Swedish striker amid Liverpool links Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash Newcastle United manager Eddie Howe's responded to swirling rumors surrounding the future of Alexander Isak denying any current negotiations over contract renewal with the Swedish forward. No Contract Talks Yet Speaking ahead of Newcastle's pre season friendly against Arsenal, Howe stated: "To my knowledge, there're no ongoing negotiations over Isak's contract. That could happen later" Despite Isak still having three years left on his deal speculation surged this week after the 25 year old missed the club's Asia tour due to reported thigh injury. Behind the Scenes Talks? Multiple outlets including The Athletic & Daily Mail, claim Isak's informed the club he wants clarity on possible move with Liverpool reportedly keen on his signature. However, Howe remained firm but diplomatic: "Isak's been amazing for the team. He's loved in the dressing room. We'd like him to continue his journey with us" He admitted Isak's under pressure: "He knows he'll be in the headlines daily. That's not easy for anyone in this position" €170M Price Tag Set Reports suggest Newcastle've placed 170 million Euro price tag on Isak an amount widely seen as deal breaker for potential buyers.
Yahoo
21 minutes ago
- Yahoo
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
Eli Lilly recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's collaboration with Gate Bioscience to develop novel therapies further strengthens its innovative capabilities, adding weight to its share price momentum amid broader market gains. We've spotted 2 risks for Eli Lilly you should be aware of, and 1 of them doesn't sit too well with us. Find companies with promising cash flow potential yet trading below their fair value. The recent positive opinion from the CHMP about Eli Lilly's Alzheimer's drug, donanemab, could significantly enhance the company's revenue and earnings forecasts. This development positions the company well for future growth, adding credibility to its strategic focus on expanding into high-demand therapeutic areas like oncology and immunology. Coupled with its collaboration with Gate Bioscience, these advances may provide substantial long-term benefits to the company's bottom line. Over the past five years, Eli Lilly's total return, which includes both share price growth and dividends, was a very large 473.44%. This long-term growth far outpaces the recent 1% rise in the broader market over the past year, bolstering investor confidence in the company's strategic trajectory and robust pipeline. In comparison to the US Pharmaceuticals industry, which saw a decline of 5.9% over the past year, Eli Lilly's sharp uptick in share price highlights its strong performance relative to industry peers. The company's earnings growth was a robust 80.9% over the past year, indicative of its potent execution in a challenging market. The current share price of US$812.69, when set against the analyst consensus price target of US$952.27, suggests there is room for potential growth. However, it also indicates investor caution, likely weighed down by concerns over competitive pressure and pricing dynamics. Investors might find reassurance in the company's ongoing manufacturing and R&D investments, which aim to mitigate risks and sustain growth in the coming years. Understand Eli Lilly's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
27 minutes ago
- Yahoo
Liverpool set to move for Malick Fofana after Federico Chiesa exit
Liverpool are keeping tabs on Olympique Lyon winger Malick Fofana as they prepare to continue their summer spending spree. According to journalist Sacha Tavolieri, the Reds are planning to move for the young Belgian but only after they have successfully offloaded Federico Chiesa. Liverpool have been one of the most active Premier League clubs in the transfer market this summer. Once Hugo Ekitike's transfer is announced, they will have spent nearly £300 million on new signings, but they're not done strengthening the squad yet. They still want to add a left winger and have been linked with Real Madrid star Rodrygo. Los Blancos are expected to demand around £87m for the Brazilian. With the way Liverpool are moving, you wouldn't put it past them to match those demands. However, Fofana offers a cost-effective alternative, but Liverpool are reportedly waiting for Chiesa to leave before they move for the Belgian starlet. Liverpool's scouting department views Fofana as a perfect fit for the team's evolving attack under manager Arne Slot. Chiesa only joined Liverpool last summer, but it was clear from the outset that he wasn't in Slot's long-term plans. The Italian made just 14 appearances across all competitions last season. His omission from Liverpool's pre-season tour in Asia is a clear indication that a summer exit is the ideal solution for all parties involved. A return to Serie A is on the cards with Atalanta, AS Roma, Fiorentina and Bologna lining up to bring the former Juventus star back to his homeland. Atalanta are leading the race and are expected to make a move once they finalise an exit for Ademola Lookman. Liverpool are demanding around £13m for Chiesa. Once that transfer goes through, they'll reinvest the proceeds into another left winger, and Fofana is firmly on their radar. Fofana is valued at £26m on Transfermarkt. He has three years left on his contract, so Lyon will likely ask for a higher fee.
